...
【24h】

Subcutaneous sarcoma. A population-based study of 129 patients

机译:皮下肉瘤。 129位患者的基于人群的研究

获取原文
           

摘要

We reviewed 129 patients with subcutaneous sarcoma diagnosed from 1964 to the end of 1985 in a population-based series of sarcoma cases from southern Sweden. The annual incidence was 0.4 per 100,000, comprising 32% of all soft-tissue sarcomas of the extremities or the trunk wall. Compared to deep-seated sarcomas, subcutaneous tumours were half the size at diagnosis, more common in the lower leg and foot, more often malignant fibrous histiocytoma, and of a lower grade of malignancy. None of the low-grade and only 7% of the high-grade tumours recurred locally after wide local excision without radiotherapy. The cumulative five-year survival for all 129 patients was 80%. Multivariate analysis identified only high grade of malignancy and the size of the tumour (greater than 5 cm) as independent prognostic factors. We conclude that systemic or local adjuvant therapy is not generally indicated for subcutaneous sarcoma because of the good prognosis and low local recurrence rate after wide excision.
机译:我们回顾了1964年至1985年底在瑞典南部基于人群的一系列肉瘤病例中诊断出的129名皮下肉瘤患者。年发病率为每100,000人中0.4,占四肢或躯干壁所有软组织肉瘤的32%。与深层肉瘤相比,皮下肿瘤在诊断时只有大小的一半,在小腿和足部更为常见,恶性纤维组织细胞瘤更常见,恶性程度较低。在不进行放射治疗的情况下,广泛的局部切除后,低级别的肿瘤均无局部复发,只有7%的高级肿瘤在局部复发。所有129名患者的五年累计生存率为80%。多变量分析仅将恶性程度高和肿瘤大小(大于5 cm)确定为独立的预后因素。我们得出的结论是,由于皮下肉瘤的预后良好,广泛切除后局部复发率较低,因此一般不建议全身或局部辅助治疗。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号